Share This Page
Drug Price Trends for PREVACID DR
✉ Email this page to a colleague
Average Pharmacy Cost for PREVACID DR
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PREVACID DR 30 MG SOLUTAB | 64764-0544-11 | 13.24691 | EACH | 2025-03-19 |
| PREVACID DR 30 MG SOLUTAB | 64764-0544-30 | 13.24691 | EACH | 2025-03-19 |
| PREVACID DR 30 MG CAPSULE | 64764-0046-13 | 13.28863 | EACH | 2025-03-19 |
| PREVACID DR 15 MG SOLUTAB | 64764-0543-11 | 13.21459 | EACH | 2025-03-19 |
| PREVACID DR 15 MG SOLUTAB | 64764-0543-30 | 13.21459 | EACH | 2025-03-19 |
| PREVACID DR 15 MG SOLUTAB | 64764-0543-11 | 13.23047 | EACH | 2025-02-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Proton Pump Inhibitors Market Analysis and Price Projections for Prevacid (Lansoprazole)
Market Overview of Proton Pump Inhibitors
The proton pump inhibitors (PPIs) market is a significant segment within the pharmaceutical industry, driven primarily by the increasing prevalence of gastroesophageal reflux disease (GERD) and other conditions involving excessive stomach acid. Here are some key points about the market:
- Market Size and Growth: The PPIs market is estimated to reach USD 12.70 billion in 2024 and is expected to grow at a CAGR of 5.14% to reach USD 16.32 billion by 2029[1].
- Regional Dominance: North America currently holds the largest market share, while the Asia Pacific region is expected to be the fastest-growing market during the forecast period[1].
Prevacid (Lansoprazole) Market Analysis
Prevacid, known generically as lansoprazole, is a prominent member of the proton pump inhibitors drug class.
Usage and Indications
Prevacid is commonly used to treat conditions such as GERD, aspiration pneumonia, Barrett's esophagus, and duodenal ulcers[2].
Market Share and Growth
While specific market share data for Prevacid is not isolated, the overall PPI market is driven by drugs like omeprazole and esomeprazole, with omeprazole capturing around 28.5% of the global market share in 2022[3].
Price Projections and Costs
Current Pricing
The cost for Prevacid 30 mg oral delayed release capsules can vary significantly:
- For a supply of 100 capsules, the cost is around $1,466.48 for the brand name, while the generic version (lansoprazole) can be as low as $26.27 for 30 capsules[2][5].
Price Comparison
Here is a comparison of the prices for Prevacid and its generic counterpart:
| Quantity | Prevacid (Brand) | Lansoprazole (Generic) |
|---|---|---|
| 100 Capsules | $1,466.48 | $26.27 (for 30 capsules) |
| 30 Capsules | N/A | $26.27 |
Discounts and Assistance Programs
Consumers can use discount cards, such as the Drugs.com Discount Card, to save up to 80% or more on prescription medicines, including Prevacid and its generic versions. These cards are accepted at most major pharmacies[2][5].
Factors Influencing Market Growth
Increasing Prevalence of GERD
The rising burden of GERD, particularly in regions like North America, is a significant driver of the PPI market. It is estimated that 40% of the U.S. population experiences GERD symptoms, with 10-20% affected on a weekly basis[1].
Shift to Over-the-Counter (OTC) Drugs
The shift from prescription-only to OTC status for some PPIs, including esomeprazole, is expected to drive market growth. This shift increases accessibility and convenience for patients[1].
Impact of COVID-19
The COVID-19 pandemic had a temporary negative impact on the PPI market due to associations between PPI use and increased risk of COVID-19 infection and poor outcomes. However, as the pandemic subsides, the market is expected to recover and grow favorably[1].
Generic Products and Side Effects
The increasing use of generic products and concerns about side effects associated with PPIs may hamper market growth. However, major players are focusing on research and development to introduce new and safer formulations[1].
Regional Market Analysis
North America
North America dominates the PPI market, driven by the high prevalence of GERD and other gastrointestinal disorders in the U.S., Canada, and Mexico. Increased PPI use in ambulatory settings and promotional activities by pharmaceutical companies also contribute to this dominance[1].
Asia Pacific
The Asia Pacific region is expected to be the fastest-growing market due to emerging markets, growing awareness, and increasing adoption of PPIs for various gastrointestinal conditions[1].
Key Players and Market Strategies
Major players in the PPI market include Bayer AG, Pfizer Inc., Takeda Pharmaceuticals, Cadila Pharmaceuticals, and AstraZeneca. These companies are engaged in research and development, new product launches, and strategic marketing to leverage market opportunities. For example, Xiromed LLC launched Omeprazole Delayed-Release Capsules in 2021, which is a generic version of Prilosec[1].
Future Outlook and Trends
- Integration with Digital Health Solutions: There is a growing trend towards integrating PPIs with digital health solutions to enhance patient compliance and monitoring.
- Global Market Expansion: Companies are expanding their market presence globally, particularly in emerging markets.
- Focus on Gastrointestinal Health Education: Educational initiatives and patient awareness campaigns are becoming more prominent to drive the market.
- Regulatory Updates and Safety Measures: Continuous updates on safety measures and regulatory compliance are crucial for market growth[4].
Key Takeaways
- The PPI market, including Prevacid, is expected to grow significantly driven by the increasing prevalence of GERD and other gastrointestinal disorders.
- North America is the largest market, while the Asia Pacific region is the fastest-growing.
- The shift to OTC status and new product launches are key drivers of market growth.
- Generic products and side effects are potential challenges, but ongoing R&D and market strategies are addressing these issues.
- Digital health integration, global expansion, and educational initiatives are future trends.
Frequently Asked Questions (FAQs)
1. What is the current market size of the proton pump inhibitors market? The proton pump inhibitors market size is expected to reach USD 12.70 billion in 2024[1].
2. Which region dominates the proton pump inhibitors market? North America currently dominates the proton pump inhibitors market[1].
3. What is the fastest-growing region in the proton pump inhibitors market? The Asia Pacific region is estimated to be the fastest-growing market during the forecast period[1].
4. How much does Prevacid 30 mg oral delayed release capsules cost? The cost for Prevacid 30 mg oral delayed release capsules can be around $1,466.48 for a supply of 100 capsules, while the generic version (lansoprazole) can cost as low as $26.27 for 30 capsules[2][5].
5. What are the major factors driving the growth of the proton pump inhibitors market? The increasing prevalence of GERD, shift to OTC status, new product launches, and growing awareness are major factors driving the market growth[1].
Cited Sources
- Mordor Intelligence: Proton Pump Inhibitors Market - PPIS - Size, Share & Analysis[1].
- Drugs.com: Prevacid Prices, Coupons, Copay Cards & Patient Assistance[2].
- Future Market Insights: Proton Pump Inhibitors Market Share & Forecast by 2033[3].
- The Business Research Company: Global Proton Pump Inhibitors Market Report 2024[4].
- Drugs.com: Lansoprazole Prices, Coupons, Copay Cards & Patient Assistance[5].
More… ↓
